^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aprepitant oral

    i
    Other names: L-754030, MK-0869, MK-869, ONO-7436
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    NK-1 antagonist
    Related drugs:
    Associations

    News

    Trials
    15d
    APHYPAP: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (clinicaltrials.gov)
    P3, N=63, Completed, University Hospital, Brest | Recruiting --> Completed
    Trial completion
    |
    aprepitant oral
    2ms
    A real-world study on the application of oral aprepitant combined with ondansetron in the treatment of breast cancer antibody-drug conjugates (ChiCTR2500109080)
    P4, N=100, Not yet recruiting, Liaoning Cancer Hospital and Institute; Liaoning Cancer Hospital and Institute
    New P4 trial • Real-world evidence
    |
    aprepitant oral • ondansetron
    8ms
    Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Rabin Medical Center
    New P1 trial • Checkpoint inhibition
    |
    aprepitant oral
    9ms
    APRE-PONV: Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (clinicaltrials.gov)
    P2, N=100, Recruiting, IWK Health Centre | Not yet recruiting --> Recruiting | Trial completion date: Apr 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    aprepitant oral
    11ms
    HN-PONV-ADR-01: Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov)
    P4, N=600, Completed, The First Affiliated Hospital of Zhengzhou University | Not yet recruiting --> Completed | Phase classification: PN/A --> P4 | Trial completion date: Jul 2025 --> Jan 2025 | Initiation date: Dec 2024 --> Jul 2024 | Trial primary completion date: May 2025 --> Dec 2024
    Trial completion • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date
    |
    aprepitant oral • ondansetron
    11ms
    Efficacy and safety of aprepitant capsules combined with immunochemotherapy for advanced non-small cell lung cancer. (ChiCTR2400094847)
    P=N/A, N=110, Huai'an First People's Hospital; Huai'an First People's Hospital
    New trial
    |
    aprepitant oral
    1year
    Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov)
    P=N/A, N=600, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University
    New trial
    |
    aprepitant oral • ondansetron
    1year
    Aprepitant mitigates paclitaxel-induced neuropathic pain in rats via suppressing inflammatory pathways in dorsal root ganglia. (PubMed, Drug Chem Toxicol)
    Aprepitant was orally administered every alternate day between days 2 and 14, with a prescribed dosage of 10 or 20 mg/kg. In addition, aprepitant application suppressed the protein expression of NF-kB in the dorsal root ganglia of paclitaxel-treated rats, as revealed by western blot analysis. Aprepitant treatment ameliorates neuropathy induced by paclitaxel, which is associated with decreasing proinflammatory cytokines and NF-kB expression.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • IL1B (Interleukin 1, beta)
    |
    NFKB1 expression
    |
    paclitaxel • aprepitant oral
    1year
    An exploratory study of the efficacy and safety of aprepitant and ondansetron alone or in combination in the prevention of nausea and vomiting after thyroid cancer surgery (ChiCTR2400089337)
    P4, N=600, Not yet recruiting, First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University
    New P4 trial • Surgery
    |
    aprepitant oral • ondansetron
    1year
    Efficacy of aprepitant combined with dual antiemetics in preventing postoperative nausea and vomiting after sleeve gastrectomy: A single-center, randomized controlled trial (ChiCTR2400087798)
    P=N/A, N=276, Recruiting, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Sc
    New trial
    |
    aprepitant oral • dexamethasone injection • ondansetron
    over1year
    A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, Chase Therapeutics Corporation | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    aprepitant oral
    over1year
    APHOS 3: EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION (clinicaltrials.gov)
    P2, N=24, Recruiting, University Hospital, Rouen
    New P2 trial
    |
    aprepitant oral